Open Payments

Butler Hospital

Type
Teaching hospital
Where
Providence, RI
Medicare CCN
414000
Received
$3,589,603 in 94 records, 2020 ($0 general, $3,589,603 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020Research payment94$3,589,603

By company

CompanyRecordsAmountYears
Biogen, Inc.4$1,548,4252020
Eli Lilly and Company7$943,7122020
Genentech, Inc.40$554,3832020
Eisai Inc.29$519,9072020
Janssen Research & Development, LLC14$23,1752020

By nature of payment

NatureRecordsAmount
Research payment94$3,589,603

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-28Janssen Research & Development, LLC$1,706Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-12-21Eisai Inc.$41,119Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-12-17Janssen Research & Development, LLC$1,374Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-12-15Genentech, Inc.$6,372Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-12-11Genentech, Inc.$1,694Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-11-26Janssen Research & Development, LLC$1,548Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-11-20Eisai Inc.$49,583Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-11-19Genentech, Inc.$26,865Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-11-10Genentech, Inc.$5,990Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-10-27Eli Lilly and Company$469Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI2020
2020-10-23Janssen Research & Development, LLC$1,956Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-10-23Janssen Research & Development, LLC$1,311Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-10-15Eisai Inc.$43,135Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-10-15Genentech, Inc.$17,730Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-10-15Genentech, Inc.$9,162Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-09-24Janssen Research & Development, LLC$1,337Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-09-23Genentech, Inc.$1,256Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-09-21Eisai Inc.$53,781Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-09-16Genentech, Inc.$15,865Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-09-14Genentech, Inc.$17,522Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-09-08Biogen, Inc.$707,792Research paymentCash or cash equivalentA Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Pa2020
2020-09-01Genentech, Inc.$30,447Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-08-27Janssen Research & Development, LLC$1,885Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-08-19Eisai Inc.$165,448Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-08-17Genentech, Inc.$22,351Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-08-03Genentech, Inc.$2,546Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-07-31Eisai Inc.$28,247Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$3,802Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$2,782Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$2,782Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$2,782Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$1,600Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$1,500Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$1,163Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$818Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-31Eisai Inc.$779Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-07-28Genentech, Inc.$1,512Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-07-27Janssen Research & Development, LLC$1,598Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-07-23Genentech, Inc.$8,900Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-07-23Genentech, Inc.$1,620Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-07-01Genentech, Inc.$2,711Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-06-25Genentech, Inc.$15,312Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-06-25Genentech, Inc.$10,890Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-06-25Janssen Research & Development, LLC$2,977Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-06-19Eisai Inc.$20,884Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-06-16Genentech, Inc.$37,511Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-06-12Genentech, Inc.$8,286Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-06-04Eisai Inc.$1,877Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-06-02Genentech, Inc.$9,766Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-06-02Genentech, Inc.$2,240Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-06-01Genentech, Inc.$3,301Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-05-19Eisai Inc.$9,612Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-05-12Genentech, Inc.$23,417Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-05-07Janssen Research & Development, LLC$3,267Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-05-04Genentech, Inc.$8,900Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-05-04Genentech, Inc.$6,166Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-04-22Eisai Inc.$22,413Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-04-16Genentech, Inc.$75,218Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-04-14Genentech, Inc.$7,182Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-04-06Eisai Inc.$1,525Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-04-01Genentech, Inc.$18,132Research paymentCash or cash equivalent DrugPHASE II STUDY FOR MODERATE AD2020
2020-04-01Genentech, Inc.$17,800Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-04-01Genentech, Inc.$8,692Research paymentCash or cash equivalent DrugPHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-03-26Janssen Research & Development, LLC$262Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-03-23Eisai Inc.$9,797Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-03-23Janssen Research & Development, LLC$670Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-03-10Genentech, Inc.$18,392Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-03-06Eisai Inc.$31,770Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-02-24Janssen Research & Development, LLC$1,598Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-02-18Genentech, Inc.$53,450Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY FOR MODERATE AD2020
2020-02-14Genentech, Inc.$26,373Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-02-09Eli Lilly and Company$324,400Research paymentCash or cash equivalentANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY2020
2020-02-03Genentech, Inc.$1,700Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY FOR MODERATE AD2020
2020-01-28Eli Lilly and Company$1,170Research paymentIn-kind items and servicesANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY2020
2020-01-27Janssen Research & Development, LLC$1,686Research paymentCash or cash equivalentAn Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression2020
2020-01-20Eisai Inc.$15,813Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety 2020
2020-01-17Eli Lilly and Company$6,397Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2020
2020-01-16Genentech, Inc.$1,274Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY FOR MODERATE AD2020
2020-01-14Genentech, Inc.$1,296Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY FOR MODERATE AD2020
2020-01-13Genentech, Inc.$15,361Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-01-07Eli Lilly and Company$495,068Research paymentCash or cash equivalentASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE2020
2020-01-07Biogen, Inc.$3,046Research paymentCash or cash equivalentMultiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-A IgG1 mAb) in Participants With Prodromal or2020
2020-01-07Eisai Inc.$1,148Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-01-07Eisai Inc.$1,148Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-01-07Eisai Inc.$1,148Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-01-07Eisai Inc.$1,148Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-01-07Eisai Inc.$1,148Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-01-07Eisai Inc.$1,148Research paymentCash or cash equivalentA Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Ef2020
2020-01-02Eli Lilly and Company$115,048Research paymentCash or cash equivalentASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI2020
2020-01-02Genentech, Inc.$5,629Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY FOR MODERATE AD2020
2020-01-02Genentech, Inc.$5,540Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD2020
2020-01-01Biogen, Inc.$816,868Research paymentCash or cash equivalentPhase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease2020
2020-01-01Biogen, Inc.$20,718Research paymentCash or cash equivalent221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease2020
2020-01-01Eli Lilly and Company$1,158Research paymentIn-kind items and servicesASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATI2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Providence CountyProvidence city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Providence, RI, county Providence County, RI, state Rhode Island; placed by its city name.

MeasurePlace (city or town)
Providence, RI
County
Providence County, RI
State
Rhode Island
Population B01003191,767664,8541,101,801
Population, 2020 census P1190,934660,7411,097,379
Median age B0100232.838.040.6
Under 18 B0100120.1%20.1%18.8%
65 and over B0100111.6%16.3%18.7%
Households B1100171,497259,210441,570
Foreign born B0500233.5%20.9%15.3%
Median household income B19013$68,119$78,787$87,796
Median family income B19113$80,994$99,120$112,375
Per capita income B19301$37,138$41,523$47,150
Poverty rate B1700120.7%13.4%11.2%
Unemployment rate B230258.2%6.6%5.8%
Civilian labor force B23025101,717358,122594,253
Mean commute (minutes) B0801325.025.925.5
Bachelor's degree or higher B1500334.6%32.3%37.7%
Housing units B2500179,423277,740485,932
Owner-occupied B2500341.4%56.9%63.6%
Renters B2500358.6%43.1%36.4%
Median home value B25077$362,200$373,600$404,200
Median gross rent B25064$1,408$1,312$1,342
White, not Hispanic B0300233.1%56.5%68.0%
Black B0300210.2%7.0%4.9%
Hispanic or Latino B0300245.3%25.6%17.7%
Asian B030026.2%4.2%3.5%
American Indian and Alaska Native B030020.3%0.2%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Providence, RI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.